Sales rise 17.29% to Rs 736.16 crore
Net profit of Epigral declined 6.84% to Rs 80.95 crore in the quarter ended March 2026 as against Rs 86.89 crore during the previous quarter ended March 2025. Sales rose 17.29% to Rs 736.16 crore in the quarter ended March 2026 as against Rs 627.63 crore during the previous quarter ended March 2025.
For the full year,net profit declined 7.19% to Rs 331.97 crore in the year ended March 2026 as against Rs 357.69 crore during the previous year ended March 2025. Sales declined 0.90% to Rs 2527.18 crore in the year ended March 2026 as against Rs 2550.13 crore during the previous year ended March 2025.
ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.Sales736.16627.63 17 2527.182550.13 -1 OPM %22.7727.62 –22.4027.87 – PBDT151.23165.28 -9 509.05673.65 -24 PBT109.54131.33 -17 340.76541.09 -37 NP80.9586.89 -7 331.97357.69 -7
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: May 02 2026 | 4:50 PM IST
